Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meloxicam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | EDNRA | P25101 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | PKM | P14618 | 2/20 | 0.77 |
| ▸ | THPO | P40225 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meloxicam SCHEMBL3752395 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL23589638 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL332632 | 0.99 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL20168549 | 0.99 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL3373822 | 0.99 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL20168506 | 0.99 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL20165003 | 0.99 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL2352397 | 0.99 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL332206 | 0.99 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA | |
| Meloxicam SCHEMBL7898655 | 0.99 | PTGS1 (0.98) | PTGS1PTGS2ABCB11GLAEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 57416 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | claimed |
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| CN-122075390-A | Preparation and application of novel cow uterus injectant | — | 2026-05-26 | — | — | CN | claimed |
| CN-122070903-A | Liquid slow-release preparation | 上海建毅腾创生物医药科技有限公司 | 2026-05-22 | — | — | CN | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122055143-A | Solid compositions containing bromhexine | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | claimed |
| WO-1997003667-A1 | METHOD OF TREATING COLONIC ADENOMAS | MERCK & CO., INC. (US) | 1997-02-06 | — | — | WO | claimed |
| EP-0594770-B1 | OXICAM OR OXICAM DERIVATIVES-CONTAINING OPHTHALMIC COMPOSITIONS | EUROPHTA LAB (MC) | 1997-01-15 | — | — | EP | claimed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1995030641-A1 | NITRO COMPOUNDS AND THEIR COMPOSITIONS HAVING ANTI-INFLAMMATORY, ANALGESIC AND ANTI-THROMBOTIC ACITIVITIES | NICOX S.A. (FR) | 1995-11-16 | — | — | WO | claimed |
| EP-0594770-A1 | OXICAM OR OXICAM DERIVATIVES-CONTAINING OPHTHALMIC COMPOSITIONS. | EUROPHTA LAB (MC) | 1994-05-04 | — | — | EP | claimed |
| WO-1993001814-A1 | OXICAM OR OXICAM DERIVATIVES-CONTAINING OPHTHALMIC COMPOSITIONS | LABORATOIRE EUROPHTA S.A. (MC) | 1993-02-04 | — | — | WO | claimed |
| EP-0002482-B1 | 4-HYDROXY-2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE-1,1-DIOXIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1981-01-07 | — | — | EP | claimed |
| US-4233299-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-11-11 | — | — | US | claimed |